Compare Quest Diagnostics Inc (DGX) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Union Pacific Corporation — how do they compare? Quest Diagnostics Inc trades at $204.9 (market cap $22.80B), while Union Pacific Corporation trades at $288.33 (market cap $171.17B). The key difference: Union Pacific Corporation is far larger — about 7.5× Quest Diagnostics Inc's market cap, and Union Pacific Corporation pays the higher dividend (1.91%). Which is the better fit depends on your goals.
| DGX | UNP | |
|---|---|---|
Market Cap | $22.80B | $171.17B |
Sector | Health | Industrials |
52-Week High | $216.02 | $289.13 |
52-Week Low | $166.42 | $214.91 |
Enterprise Value | $28.82B | $201.64B |
Dividend Yield | 1.67% | 1.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Union Pacific (UNP) trades at $289.13, up 0.76% with a bullish technical signal. The company shows strong profitability with 29.2% net margins and 40.69% ROE, though valuation multiples remain elevated. Recent earnings beat expectations in Q1 2026, and the proposed Norfolk Southern merger represents a significant growth catalyst. Cash flow generation remains robust at $9.29B from operations in 2025.
Outlook remains positive with analyst consensus at Buy and $304.23 price target, though regulatory hurdles for the merger and elevated RSI levels pose near-term risks. The stock offers dividend growth potential with stable operational performance, but faces headwinds from industry consolidation concerns and potential legal liabilities from ongoing class action litigation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
